- Home
- RRR vs IDYA Comparison
RRR vs IDYA Comparison
Compare RRR & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RRR | IDYA |
|---|---|---|
| Founded | 1976 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 2.9B |
| IPO Year | 2016 | 2019 |
Fundamental Metrics
Financial Performance| Metric | RRR | IDYA |
|---|---|---|
| Price | $63.30 | $33.86 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 14 |
| Target Price | ★ $61.40 | $49.42 |
| AVG Volume (30 Days) | 773.1K | ★ 1.0M |
| Earning Date | 10-28-2025 | 11-04-2025 |
| Dividend Yield | ★ 3.23% | N/A |
| EPS Growth | ★ 15.51 | N/A |
| EPS | ★ 3.14 | N/A |
| Revenue | ★ $1,995,401,000.00 | $214,834,000.00 |
| Revenue This Year | $4.13 | $2,434.86 |
| Revenue Next Year | $3.47 | N/A |
| P/E Ratio | $20.12 | ★ N/A |
| Revenue Growth | 4.69 | ★ 5377.66 |
| 52 Week Low | $35.09 | $13.45 |
| 52 Week High | $64.25 | $37.08 |
Technical Indicators
Market Signals| Indicator | RRR | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 67.60 | 52.66 |
| Support Level | $62.18 | $33.11 |
| Resistance Level | $64.25 | $34.45 |
| Average True Range (ATR) | 1.54 | 1.38 |
| MACD | 0.62 | -0.31 |
| Stochastic Oscillator | 88.60 | 18.97 |
Price Performance
Historical ComparisonAbout RRR Red Rock Resorts Inc.
Red Rock Resorts Inc along with its subsidiary is a gaming, development and management company that develops and operates strategically-located casino and entertainment properties. Its casino properties are conveniently located throughout the Las Vegas valley and provide its customers a wide variety of entertainment and dining options. The majority of revenue is derived from Casinos.
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.